Sandoz

Generics producer Sandoz is planning to invest roughly US$90 million at its site in Ljubljana to establish a dedicated centre for development of biosimilars by 2026. As part of the process to spin off from Novartis, Sandoz holds part of the Slovenian pharmaceutical company Lek.

Lek, the Ljubljana-based pharmaceutical company which is part of the Swiss generics group Sandoz, will build a US$400 million high-tech production centre for biosimilars in Lendava, in north-eastern Slovenia. The investment is to create around 300 new jobs.

The turnover of Romanian drug manufacturers, distributors and pharmacies was 66.6 billion lei in 2020, up 2.6 percent from 2019 and over 100 percent higher compared to 2010, shows a survey by KeysFin - one of the most important providers of business information solutions in Romania - based on Finance Ministry figures.

Ljubljana – The Swiss pharma giant Novartis continued to invest in its R&D and production capacities in Slovenia through its subsidiaries Lek, Sandoz and Novartis Pharma Services last year. Despite the Covid-19 epidemic, it invested EUR 204 million in the country, show figures presented on Tuesday.

Greece's EOF drug safety authority has recalled two widely used stomach acid blockers on the recommendation of the European and American authorities after laboratory tests found them to contain the potentially dangerous chemical NDMA (N-Nitroso-dimethylamine).